» Articles » PMID: 28843484

Cell-Cycle Position of Single MYC-Driven Cancer Cells Dictates Their Susceptibility to a Chemotherapeutic Drug

Overview
Journal Cell Syst
Publisher Cell Press
Date 2017 Aug 28
PMID 28843484
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

While many tumors initially respond to chemotherapy, regrowth of surviving cells compromises treatment efficacy in the long term. The cell-biological basis of this regrowth is not understood. Here, we characterize the response of individual, patient-derived neuroblastoma cells driven by the prominent oncogene MYC to the first-line chemotherapy, doxorubicin. Combining live-cell imaging, cell-cycle-resolved transcriptomics, and mathematical modeling, we demonstrate that a cell's treatment response is dictated by its expression level of MYC and its cell-cycle position prior to treatment. All low-MYC cells enter therapy-induced senescence. High-MYC cells, by contrast, disable their cell-cycle checkpoints, forcing renewed proliferation despite treatment-induced DNA damage. After treatment, the viability of high-MYC cells depends on their cell-cycle position during treatment: newborn cells promptly halt in G phase, repair DNA damage, and form re-growing clones; all other cells show protracted DNA repair and ultimately die. These findings demonstrate that fast-proliferating tumor cells may resist cytotoxic treatment non-genetically, by arresting within a favorable window of the cell cycle.

Citing Articles

Towards understanding cancer dormancy over strategic hitching up mechanisms to technologies.

Yang S, Seo J, Choi J, Kim S, Kuk Y, Park K Mol Cancer. 2025; 24(1):47.

PMID: 39953555 PMC: 11829473. DOI: 10.1186/s12943-025-02250-9.


Targeting therapy-persistent residual disease.

Sun X, Wu L, Altschuler S, Hata A Nat Cancer. 2024; 5(9):1298-1304.

PMID: 39289594 DOI: 10.1038/s43018-024-00819-9.


A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma.

Ryl T, Afanasyeva E, Hartmann T, Schwermer M, Schneider M, Schroder C Commun Biol. 2024; 7(1):919.

PMID: 39079981 PMC: 11289481. DOI: 10.1038/s42003-024-06596-6.


A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations.

Saldana-Guerrero I, Montano-Gutierrez L, Boswell K, Hafemeister C, Poon E, Shaw L Nat Commun. 2024; 15(1):3745.

PMID: 38702304 PMC: 11068915. DOI: 10.1038/s41467-024-47945-7.


Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance.

Maleki E, Bahrami A, Matin M Genes Dis. 2023; 11(1):189-204.

PMID: 37588236 PMC: 10425754. DOI: 10.1016/j.gendis.2022.11.025.